-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy

Sponsor: educational grants from AstraZeneca, Lilly, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Provided by National Comprehensive Cancer Network with Clinical Care Options, LLC
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
apoptosis, apheresis, Adult, therapy sequence, antibodies, Biological, Leukemia, Non-Biological, Lymphoma (any), CLL, Diseases, Elderly, Combinations, CAR-Ts, Therapies, cellular interactions, Biological Processes, Technology and Procedures, epigenetics, cytogenetics, Study Population, Lymphoid Malignancies, genomics, genetic profiling, molecular testing, NGS, molecular interactions
Friday, December 4, 2020: 7:00 AM-10:00 AM
William G. Wierda, MD, PhD, University of Texas M.D. Anderson Cancer Center
Wierda: Sunesis: Research Funding; Miragen: Research Funding; Oncternal Therapeutics, Inc: Research Funding; Cyclacel: Research Funding; Gilead Sciences: Research Funding; Acerta Pharma: Research Funding; Pharmacyclics LLC: Research Funding; Genentech: Research Funding; Abbvie: Research Funding; GSK/Novartis: Research Funding; Juno Therapeutics: Research Funding; KITE Pharma: Research Funding; Loxo Oncology, Inc.: Research Funding; Janssen: Research Funding; Xencor: Research Funding.
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center and Brian T. Hill, MD, Cleveland Clinic Foundation
Abramson: Kite Pharma: Consultancy; Morphosys: Consultancy; Novartis: Consultancy; Abbvie: Consultancy; Allogene: Consultancy; Celgene: Consultancy; C4 therapeutics: Consultancy; Karyopharm: Consultancy. Hill: Karyopharm: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Takeda: Research Funding; Genentech: Consultancy, Honoraria, Research Funding; AstraZenica: Consultancy, Honoraria, Research Funding; Beigene: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria.
This NCCN-developed webinar presents a great opportunity for clinicians to learn about the latest therapeutic advances in chronic lymphocytic leukemia (CLL). During the live event, the faculty will give a snapshot overview of advances in CLL including risk assessment, molecular profiling, along with current and emerging therapeutics. This overview will be followed by panel discussions of various patient case scenarios with expert recommendations and supporting clinical data. Ongoing clinical trials and promising agents and combinations currently under investigation will also be discussed. A moderated panel discussion and an audience question and answer session will close each section of the symposium and will provide further perspectives on how the experts interpret the available clinical data and apply them in their practice. Participants will be able to fully interact and contribute to the cases discussed by the panel via the virtual platform. Throughout the webinar, participants will have the opportunity to directly query the faculty for further clarification of the education or to obtain expert perspective on their own treatment challenges. The webinar will also feature review and presentation of the latest updates to the NCCN guideline treatment algorithms to help guide practical application.
See more of: Satellite Symposia